JP2023050045A - Antiviral agent and antiviral processed product containing the same - Google Patents

Abstract

To provide an antiviral agent having excellent antiviral property and an antiviral processed product containing the same.SOLUTION: Antiviral agents containing silver molybdate and zinc 2-ethylhexanoate have excellent antiviral properties. In addition, an antiviral processed product in which the antiviral agent is blended also has excellent antiviral properties, in particular, by blending 0.1 to 10 pts.mass of the antiviral agent to 100 pts.mass of the antiviral processed product, the antiviral properties become remarkable.SELECTED DRAWING: None

Description

TECHNICAL FIELD The present invention relates to an antiviral agent and an antiviral processed product containing the same.

Since enveloped viruses such as influenza virus and coronavirus, or non-enveloped viruses such as norovirus, cause various diseases, antiviral compositions have been developed to control these viruses. ing. (Patent document 1)

JP 2015-071752

An object of the present invention is to provide an antiviral agent having excellent antiviral performance and an antiviral processed product containing the same.

Means for Invention to Solve

The present inventors have arrived at the present invention as a result of intensive studies in order to solve such problems. That is, the present invention
[1] An antiviral agent containing silver molybdate and zinc 2-ethylhexanoate.
[2] The above antiviral agent, wherein the content of silver molybdate is 5 to 25% by weight with respect to the total content of silver molybdate and zinc 2-ethylhexanoate.
[3] An antiviral processed product containing the above antiviral agent.
[4] The above antiviral processed product, in which the above antiviral agent is blended in an amount of 0.1 to 10 parts by weight per 100 parts by weight of the antiviral processed product.
I will provide a.

An object of the present invention is to provide an antiviral agent having excellent antiviral properties and an antiviral processed product containing the same.

Silver molybdate used in the antiviral agent of the present invention is obtained, for example, by solid-liquid separation of precipitates deposited by mixing an aqueous solution of silver salt and an aqueous solution of molybdate. It can be obtained by drying the precipitate in a wet state.
Examples of the silver salt include silver nitrate, silver acetate, silver sulfate and the like. Examples of the molybdate include sodium molybdate, potassium molybdate, and ammonium molybdate.

Zinc 2-ethylhexanoate used in the antiviral agent of the present invention can be obtained, for example, by metathesis of zinc sulfate and ammonium caprylate. Zinc 2-ethylhexanoate sold by Fuji Film Wako Pure Chemical Industries, Ltd., etc. can also be used.

Since zinc 2-ethylhexanoate is a viscous liquid at room temperature, it should be supported on a carrier having an oil absorption of 1.5 to 5.0 ml/g (measured according to JIS K5101-13-1). may Examples of the carrier include calcium silicate and silicon dioxide having the above oil absorption. Examples of calcium silicate include Fluorite (registered trademark) R and RT (manufactured by Tomita Pharmaceutical Co., Ltd.), and examples of silicon dioxide include Toxil (registered trademark) NR (Oriental Silicas Corporation). When used by being carried on a carrier, the amount (weight/weight) of zinc 2-ethylhexanoate to the carrier is usually 4 times or less.

The antiviral agent of the present invention preferably has a silver molybdate content in the range of 5 to 25% by weight based on the total content of silver molybdate and zinc 2-ethylhexanoate.

If necessary, the antiviral agent of the present invention may be blended with an anti-discoloration agent, an ultraviolet absorber, and the like.

The antiviral agent of the present invention is blended into plastic agents such as resin films or sheets, coating agents such as paints and surface treatment agents, adhesives, fibers, paper, and the like, and used as antiviral processed products. The antiviral agent of the present invention can exhibit excellent antiviral properties particularly when blended with a resin component.

Examples of such resin components include alkyd resins, polyester resins, acrylic resins, urethane resins, epoxy resins, fluorine resins, silicone resins, unsaturated polyester resins, melamine resins, phenolic resins, nitrocellulose resins, vinyl acetate resins, vinyl chloride resins. resins, polyolefin resins, acrylonitrile-butadiene-styrene resins, and the like.

The amount of the antiviral agent of the present invention to be blended may vary depending on the material to be blended, but is usually 0.1 to 10 parts by weight per 100 parts by weight of the antiviral processed product.

The above-mentioned antiviral processed products include wall materials, handrails, flooring materials, wooden floor materials, kitchen counters, furniture, wallpaper and other living environment materials, electrical product materials such as refrigerator and air conditioner housings, textile products such as filters, It is used in electrical product parts such as protective films for the image display of portable electronic devices, industrial product parts such as seats and floor mats for automobiles and trains, and packaging parts such as wrapping paper and cardboard. It is suitably used as various members having

The term "antiviral" in the present invention includes reducing infectivity by lowering viral infectivity, suppressing viral proliferation, and killing viruses.

The present invention will be specifically described below with reference to Formulation Examples and Test Examples, but the present invention is not limited to these.

(Preparation of silver molybdate)
430.0 g of ion-exchanged water was placed in a 1-liter glass beaker, and 50.0 g of silver nitrate (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.) was added thereto and stirred and dissolved to prepare an aqueous solution of silver nitrate. In addition, 463.4 g of ion-exchanged water was placed in a 1-liter separable round-bottomed flask, and 36.6 g of sodium molybdate dihydrate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was added, stirred and dissolved, and molybdic acid was dissolved. A sodium aqueous solution was prepared.

Next, silver molybdate was precipitated by dropping an aqueous solution of silver nitrate into the aqueous solution of sodium molybdate while stirring. After suction-filtrating the liquid containing silver molybdate obtained here, silver molybdate was obtained by drying the obtained filter cake.

Formulation example 1

After mixing 1.0 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zinc octoate purity 99%) and 0.25 g of Fluorite RT, 0.25 g of silver molybdate prepared above. were mixed to obtain an antiviral agent (hereinafter referred to as Formulation-1).

Formulation example 2

After mixing 1.125 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zinc octoate purity 99%) and 0.281 g of Fluorite RT, 0.125 g of the silver molybdate prepared above was added. An antiviral agent (hereinafter referred to as Formulation-2) was obtained by mixing.

Examples of comparative formulations

0.25 g of the silver molybdate prepared above was used as a comparative preparation (hereinafter referred to as comparative preparation-1).
In addition, 1.0 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zinc octylate purity 99%) was used as a comparative formulation (hereinafter referred to as comparative formulation-2).

<Preparation of test piece of antiviral resin molding>
After mixing 100 g of ZEST-1300 (polyvinyl chloride, manufactured by Shin-Daiichi PVC), 45 g of diisononyl phthalate, 6.2 g of epoxidized soybean oil, and 12.3 g of LBK-793K (manufactured by Sakai Chemical Industry Co., Ltd.), a stabilizer for polyvinyl chloride resin, A vinyl chloride sol was obtained by kneading at 170° C. with a Laboplastomill. 100 g of the vinyl chloride sol and the formulation-1 were kneaded to obtain a resin compound. After pressing the resin compound for 3 minutes with a press molding machine heated to 180° C., it is cooled to room temperature to obtain a polyvinyl chloride sheet with a thickness of 0.5 mm, and the sheet is cut into 5 cm×5 cm. A test piece was thus obtained. Two test pieces were prepared.

(Antiviral test against influenza virus)
In accordance with ISO21702, influenza virus H3N2 strain (influenza A virus: A/Hong Kong/8/68: TC adapted ATCC VR-1679) was cultured with MDCK cells (canine kidney-derived cells), and the virus infection titer was 2 × 10 ⁷ Plaque Forming. Units/ml (hereafter referred to as PFU/ml) of the test influenza virus suspension were obtained.

Place one of the test pieces in a plastic petri dish, drop 0.4 ml of the above-described test influenza virus suspension in the approximate center area of the test piece, and then place a 4 cm square so as to cover the entire test virus suspension. A polyethylene film was placed and stored at 25° C. and 95% humidity for 24 hours. Then, the test influenza virus suspension between the test piece and the polyethylene film was washed out with 10 ml of SCDLP medium (Nippon Pharmaceutical Co., Ltd.), and this washing liquid was washed with EMEM medium 10 times, 100 times, 1000 times, 10000 times and 100000 times. After diluting 1-fold, the influenza virus infectivity titer (IV infectivity logarithm) was measured by the plaque assay method on MDCK cells.

(Antiviral test against feline calicivirus)
According to ISO21702, feline calicivirus strain F-9 (Feline calicivirus, Strain: F-9 ATCC VR-782) was cultured with CRFK cells (feline kidney-derived cells), and the virus infectious titer was 2×10 ⁷ Plaque Forming Units/ml ( hereinafter referred to as PFU/ml) of the test feline calicivirus suspension was obtained.

Place one of the test pieces prepared above in a plastic petri dish, drop 0.4 ml of the above-described test feline calicivirus suspension in the approximate center area of the test piece, and then add 4 cm to cover the entire test virus suspension. A corner polyethylene film was placed and stored at 25° C. and 95% humidity for 24 hours. Next, the test feline calicivirus suspension between the test piece and the polyethylene film was washed out with 10 ml of SCDLP medium (Nippon Pharmaceutical Co., Ltd.), and this washing liquid was washed with EMEM medium (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) 10 times, 100 times. It was diluted 1-fold, 1000-fold, 10000-fold and 100000-fold, and feline calicivirus infectivity (FCV infectivity logarithm) was measured on CRFK cells by plaque assay method.

For Formulation-2, Comparative Formulation-1, and Comparative Formulation-2, prepare two test pieces each in the same manner as described above, and conduct an antiviral test against influenza virus and feline calicivirus in the same manner as the above test. bottom.

Table 1 summarizes the test results.

[Table 1]
Viral infectivity titer measurement results

Claims (4)

An antiviral agent containing silver molybdate and zinc 2-ethylhexanoate. 2. The antiviral agent according to claim 1, wherein the content of silver molybdate is 5 to 25% by weight with respect to the total content of silver molybdate and zinc 2-ethylhexanoate. An antiviral processed product containing the antiviral agent according to claim 1 or 2. The antiviral processed product according to claim 3, wherein the antiviral agent according to claim 1 or 2 is blended in an amount of 0.1 to 10 parts by weight per 100 parts by weight of the antiviral processed product.